{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:34:48Z","timestamp":1793799288038,"version":"4.6.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bispecific antibodies (bsAbs), designed to recognize two distinct antigens or epitopes, enable innovative mechanisms of action for emerging generations of cancer immunotherapies. Despite their potential, bsAb therapeutics face several challenges related to their biodistribution and pharmacokinetics, which often result in a suboptimal efficacy\/toxicity balance. Starting with a brief description of the relevance of bsAbs in cancer immunotherapy, this review aims to critically analyze the synergistic potential of nanotechnology and bsAb technology oriented to enhance therapeutic efficiency while reducing toxicity. This synergy can be achieved through several strategies: (i) bsAbs may function as targeting ligands to improve the biodistribution of drug-loaded nanocarriers; (ii) therapeutic bsAbs incorporated into nanocarriers may easily overcome biological barriers and reach their target; and (iii) bsAbs can be generated in vivo using mRNA-loaded nanocarriers encoding them. This review addresses challenges in these emerging areas and provides insights into future directions for this promising field.<\/jats:p>","DOI":"10.1186\/s12943-025-02501-9","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:36:59Z","timestamp":1763401019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bispecific antibodies and nanotechnology:\u00a0a strategic alliance in cancer immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Elisa","family":"Battistini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lapuhs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Garrido-Areal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Rivas-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Zagorac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"\u00c1lvarez-Vallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Sanjurjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2501_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301\u201319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6.","journal-title":"Nat Rev Drug Discov"},{"key":"2501_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1291836","volume":"14","author":"X Guo","year":"2023","unstructured":"Guo X, Wu Y, Xue Y, Xie N, Shen G. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment. Front Immunol. 2023;14:1291836. https:\/\/doi.org\/10.3389\/fimmu.2023.1291836.","journal-title":"Front Immunol"},{"key":"2501_CR3","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1158\/1078-0432.CCR-20-3770","volume":"27","author":"B Blanco","year":"2021","unstructured":"Blanco B, Dom\u00ednguez-Alonso C, Alvarez-Vallina L. Bispecific immunomodulatory antibodies for cancer immunotherapy. Clin Cancer Res. 2021;27:5457\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3770.","journal-title":"Clin Cancer Res"},{"key":"2501_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","volume":"359","author":"A Beishenaliev","year":"2023","unstructured":"Beishenaliev A, Loke YL, Goh SJ, Geo HN, Mugila M, Misran M, et al. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review. J Control Release. 2023;359:268\u201386. https:\/\/doi.org\/10.1016\/j.jconrel.2023.05.032.","journal-title":"J Control Release"},{"key":"2501_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","volume":"46","author":"Y Hong","year":"2023","unstructured":"Hong Y, Nam S-M, Moon A. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Arch Pharm Res. 2023;46:131\u201348. https:\/\/doi.org\/10.1007\/s12272-023-01433-6.","journal-title":"Arch Pharm Res"},{"key":"2501_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","volume":"34","author":"PA Baeuerle","year":"2022","unstructured":"Baeuerle PA, Wesche H. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr Opin Oncol. 2022;34:552\u20138. https:\/\/doi.org\/10.1097\/CCO.0000000000000869.","journal-title":"Curr Opin Oncol"},{"key":"2501_CR7","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"issue":"7","key":"2501_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","volume":"24","author":"A Fenis","year":"2024","unstructured":"Fenis A, Demaria O, Gauthier L, Vivier E, Narni-Mancinelli E. New immune cell engagers for cancer immunotherapy. Nat Rev Immunol. 2024;24(7):471\u201386. https:\/\/doi.org\/10.1038\/s41577-023-00982-7.","journal-title":"Nat Rev Immunol"},{"key":"2501_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276. https:\/\/doi.org\/10.3389\/fimmu.2022.1035276.","journal-title":"Front Immunol"},{"key":"2501_CR10","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39:3391\u2013402. https:\/\/doi.org\/10.1200\/JCO.21.00662.","journal-title":"J Clin Oncol"},{"key":"2501_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","volume":"20","author":"T Zhang","year":"2023","unstructured":"Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med. 2023;20:181\u201395. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0002.","journal-title":"Cancer Biol Med"},{"key":"2501_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Cadonilimab. First approval. Drugs. 2022;82:1333\u20139. https:\/\/doi.org\/10.1007\/s40265-022-01761-9.","journal-title":"Drugs"},{"key":"2501_CR13","doi-asserted-by":"publisher","first-page":"e2313791","DOI":"10.1002\/adma.202313791","volume":"36","author":"A Vaidya","year":"2024","unstructured":"Vaidya A, Moore S, Chatterjee S, Guerrero E, Kim M, Farbiak L, et al. Expanding RNAi to kidneys, lungs, and spleen via selective organ targeting (SORT) SiRNA lipid nanoparticles. Adv Mater. 2024;36:e2313791. https:\/\/doi.org\/10.1002\/adma.202313791.","journal-title":"Adv Mater"},{"key":"2501_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard SA, Siegwart DJ. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater. 2023;8:282\u2013300. https:\/\/doi.org\/10.1038\/s41578-022-00529-7.","journal-title":"Nat Rev Mater"},{"key":"2501_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","volume":"320","author":"AC Marques","year":"2020","unstructured":"Marques AC, Costa PJ, Velho S, Amaral MH. Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J Control Release. 2020;320:180\u2013200. https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.035.","journal-title":"J Control Release"},{"key":"2501_CR16","doi-asserted-by":"publisher","first-page":"10045","DOI":"10.2147\/IJN.S479270","volume":"19","author":"K-W Ho","year":"2024","unstructured":"Ho K-W, Liu Y-L, Liao T-Y, Liu E-S, Cheng T-L. Strategies for non-covalent attachment of antibodies to pegylated nanoparticles for targeted drug delivery. Int J Nanomed. 2024;19:10045\u201364. https:\/\/doi.org\/10.2147\/IJN.S479270.","journal-title":"Int J Nanomed"},{"key":"2501_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.molimm.2018.01.010","volume":"96","author":"SK Nikkhoi","year":"2018","unstructured":"Nikkhoi SK, Rahbarizadeh F, Ranjbar S, Khaleghi S, Farasat A. Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting. Mol Immunol. 2018;96:98\u2013109. https:\/\/doi.org\/10.1016\/j.molimm.2018.01.010.","journal-title":"Mol Immunol"},{"key":"2501_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.7150\/thno.13069","volume":"6","author":"S-C Wu","year":"2016","unstructured":"Wu S-C, Chen Y-J, Wang H-C, Chou M-Y, Chang T-Y, Yuan S-S, et al. Bispecific antibody conjugated manganese-based magnetic engineered iron oxide for imaging of HER2\/neu- and EGFR-expressing tumors. Theranostics. 2016;6:118\u201330. https:\/\/doi.org\/10.7150\/thno.13069.","journal-title":"Theranostics"},{"key":"2501_CR19","doi-asserted-by":"publisher","first-page":"9930","DOI":"10.1016\/j.biomaterials.2014.08.032","volume":"35","author":"C-H Kao","year":"2014","unstructured":"Kao C-H, Wang J-Y, Chuang K-H, Chuang C-H, Cheng T-C, Hsieh Y-C, et al. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials. 2014;35:9930\u201340. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.08.032.","journal-title":"Biomaterials"},{"key":"2501_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87271-2","volume":"11","author":"W-W Lin","year":"2021","unstructured":"Lin W-W, Cheng Y-A, Li C-C, Ho K-W, Chen H-J, Chen I-JU, et al. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. Sci Rep. 2021;11:7598. https:\/\/doi.org\/10.1038\/s41598-021-87271-2.","journal-title":"Sci Rep"},{"key":"2501_CR21","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1039\/c9bm00323a","volume":"7","author":"Y-A Cheng","year":"2019","unstructured":"Cheng Y-A, Chen I-J, Su Y-C, Cheng K-W, Lu Y-C, Lin W-W, et al. Enhanced drug internalization and therapeutic efficacy of pegylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer. Biomater Sci. 2019;7:3404\u201317. https:\/\/doi.org\/10.1039\/c9bm00323a.","journal-title":"Biomater Sci"},{"key":"2501_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1126\/scitranslmed.abm1262","volume":"15","author":"E Moles","year":"2023","unstructured":"Moles E, Howard CB, Huda P, Karsa M, McCalmont H, Kimpton K, et al. Delivery of pegylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia. Sci Transl Med. 2023;15:696. https:\/\/doi.org\/10.1126\/scitranslmed.abm1262.","journal-title":"Sci Transl Med"},{"key":"2501_CR23","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/adhm.201600263","volume":"5","author":"CB Howard","year":"2016","unstructured":"Howard CB, Fletcher N, Houston ZH, Fuchs AV, Boase NRB, Simpson JD, et al. Overcoming instability of antibody-nanomaterial conjugates: next generation targeted nanomedicines using bispecific antibodies. Adv Healthc Mater. 2016;5:2055\u201368. https:\/\/doi.org\/10.1002\/adhm.201600263.","journal-title":"Adv Healthc Mater"},{"key":"2501_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801607","volume":"8","author":"J Cui","year":"2019","unstructured":"Cui J, Ju Y, Houston ZH, Glass JJ, Fletcher NL, Alcantara S, et al. Modulating targeting of poly(ethylene glycol) particles to tumor cells using bispecific antibodies. Adv Healthc Mater. 2019;8:e1801607. https:\/\/doi.org\/10.1002\/adhm.201801607.","journal-title":"Adv Healthc Mater"},{"key":"2501_CR25","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1021\/acs.molpharmaceut.3c00558","volume":"20","author":"M Lim","year":"2023","unstructured":"Lim M, Fletcher NL, Saunus JM, McCart Reed AE, Chittoory H, Simpson PT, et al. Targeted hyperbranched nanoparticles for delivery of doxorubicin in breast cancer brain metastasis. Mol Pharm. 2023;20:6169\u201383. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00558.","journal-title":"Mol Pharm"},{"key":"2501_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121416","volume":"283","author":"PW Janowicz","year":"2022","unstructured":"Janowicz PW, Houston ZH, Bunt J, Fletcher NL, Bell CA, Cowin G, et al. Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption. Biomaterials. 2022;283:121416. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121416.","journal-title":"Biomaterials"},{"key":"2501_CR27","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1080\/10717544.2018.1466936","volume":"25","author":"C-Y Su","year":"2018","unstructured":"Su C-Y, Chen M, Chen L-C, Ho Y-S, Ho H-O, Lin S-Y, et al. Bispecific antibodies (anti-mPEG\/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Drug Deliv. 2018;25:1066\u201379. https:\/\/doi.org\/10.1080\/10717544.2018.1466936.","journal-title":"Drug Deliv"},{"key":"2501_CR28","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.2147\/IJN.S301237","volume":"16","author":"W-J Cheng","year":"2021","unstructured":"Cheng W-J, Lin S-Y, Chen M, Chen L-C, Ho H-O, Chuang K-H, et al. Active tumoral\/tumor environmental dual-targeting by non-covalently arming with trispecific antibodies or dual-bispecific antibodies on docetaxel-loaded mPEGylated nanocarriers to enhance chemotherapeutic efficacy and minimize systemic toxicity. Int J Nanomed. 2021;16:4017\u201330. https:\/\/doi.org\/10.2147\/IJN.S301237.","journal-title":"Int J Nanomed"},{"key":"2501_CR29","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.2147\/IJN.S388066","volume":"17","author":"W-J Cheng","year":"2022","unstructured":"Cheng W-J, Lin S-Y, Chuang K-H, Chen M, Ho H-O, Chen L-C, et al. Combined docetaxel\/pictilisib-loaded mPEGylated nanocarriers with dual HER2 targeting antibodies for synergistic chemotherapy of breast cancer. Int J Nanomed. 2022;17:5353\u201374. https:\/\/doi.org\/10.2147\/IJN.S388066.","journal-title":"Int J Nanomed"},{"key":"2501_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.201900202","volume":"3","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Fletcher NL, Gemmell A, Houston ZH, Howard CB, Blakey I, et al. Investigation of the therapeutic potential of a synergistic delivery system through dual controlled release of camptothecin\u2013doxorubicin. Adv Ther. 2020;3:1900202. https:\/\/doi.org\/10.1002\/adtp.201900202.","journal-title":"Adv Ther"},{"key":"2501_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123990","volume":"654","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Gu X, Huang L, Yang Y, He J. Enhancing precision medicine: bispecific antibody-mediated targeted delivery of lipid nanoparticles for potential cancer therapy. Int J Pharm. 2024;654:123990. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.123990.","journal-title":"Int J Pharm"},{"key":"2501_CR32","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jconrel.2024.02.007","volume":"367","author":"A Logan","year":"2024","unstructured":"Logan A, Howard CB, Huda P, Kimpton K, Ma Z, Thurecht KJ, et al. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma. J Control Release. 2024;367:806\u201320. https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.007.","journal-title":"J Control Release"},{"key":"2501_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.20.629467","author":"A Amabile","year":"2024","unstructured":"Amabile A, Phelan M, Yu Z, Silva P, Marks A, Morla-Folch J, et al. Bispecific antibody targeting of lipid nanoparticles. Preprint [bioRxiv]. 2024. https:\/\/doi.org\/10.1101\/2024.12.20.629467.","journal-title":"Preprint [bioRxiv]"},{"key":"2501_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15507","volume":"8","author":"Y-C Su","year":"2017","unstructured":"Su Y-C, Burnouf P-A, Chuang K-H, Chen B-M, Cheng T-L, Roffler SR. Conditional internalization of pegylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nat Commun. 2017;8:15507. https:\/\/doi.org\/10.1038\/ncomms15507.","journal-title":"Nat Commun"},{"key":"2501_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.actbio.2020.04.029","volume":"111","author":"I-J Chen","year":"2020","unstructured":"Chen I-J, Cheng Y-A, Ho K-W, Lin W-W, Cheng K-W, Lu Y-C, et al. Bispecific antibody (HER2 \u00d7 mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Acta Biomater. 2020;111:386\u201397. https:\/\/doi.org\/10.1016\/j.actbio.2020.04.029.","journal-title":"Acta Biomater"},{"key":"2501_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2019.102076","volume":"21","author":"CL Parker","year":"2019","unstructured":"Parker CL, McSweeney MD, Lucas AT, Jacobs TM, Wadsworth D, Zamboni WC, et al. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2. Nanomedicine. 2019;21:102076. https:\/\/doi.org\/10.1016\/j.nano.2019.102076.","journal-title":"Nanomedicine"},{"key":"2501_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-00752-w","volume":"19","author":"K-W Ho","year":"2021","unstructured":"Ho K-W, Chen I-JU, Cheng Y-A, Liao T-Y, Liu E-S, Chen H-J, et al. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting pegylated liposomal doxorubicin to enhance anti-tumor activity. J Nanobiotechnol. 2021;19:16. https:\/\/doi.org\/10.1186\/s12951-020-00752-w.","journal-title":"J Nanobiotechnol"},{"key":"2501_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.17.618962","author":"B Dietmair","year":"2024","unstructured":"Dietmair B, Humphries J, Mercer TR, Thurecht KJ, Howard CB, Cheetham SW. Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell-surface markers. Preprint [bioRxiv]. 2024. https:\/\/doi.org\/10.1101\/2024.10.17.618962.","journal-title":"Preprint [bioRxiv]"},{"key":"2501_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201700607","volume":"7","author":"AJ Sivaram","year":"2018","unstructured":"Sivaram AJ, Wardiana A, Howard CB, Mahler SM, Thurecht KJ. Recent advances in the generation of antibody-nanomaterial conjugates. Adv Healthc Mater. 2018;7:1700607. https:\/\/doi.org\/10.1002\/adhm.201700607.","journal-title":"Adv Healthc Mater"},{"key":"2501_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1021\/acs.bioconjchem.6b00638","volume":"28","author":"SAM Van Lith","year":"2017","unstructured":"Van Lith SAM, Van Duijnhoven SMJ, Navis AC, Leenders WPJ, Dolk E, Wennink JWH, et al. Legomedicine- a versatile chemo-enzymatic approach for the preparation of targeted dual-labeled Llama antibody\u2013nanoparticle conjugates. Bioconjug Chem. 2017;28:539\u201348. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00638.","journal-title":"Bioconjug Chem"},{"key":"2501_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-00680-9","volume":"18","author":"Y-A Cheng","year":"2020","unstructured":"Cheng Y-A, Wu T-H, Wang Y-M, Cheng T-L, Chen I-J, Lu Y-C, et al. Humanized bispecific antibody (mPEG \u00d7 HER2) rapidly confers pegylated nanoparticles tumor specificity for multimodality imaging in breast cancer. J Nanobiotechnol. 2020;18:118. https:\/\/doi.org\/10.1186\/s12951-020-00680-9.","journal-title":"J Nanobiotechnol"},{"key":"2501_CR42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"MER O\u2019Brien","year":"2004","unstructured":"O\u2019Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdh097.","journal-title":"Ann Oncol"},{"key":"2501_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020.","journal-title":"J Control Release"},{"key":"2501_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.201900170","volume":"3","author":"N d\u2019 Avanzo","year":"2020","unstructured":"d\u2019Avanzo N, Celia C, Barone A, Carafa M, Di Marzio L, Santos HA, et al. Immunogenicity of polyethylene glycol based nanomedicines: mechanisms, clinical implications and systematic approach. Adv Ther. 2020;3:1900170. https:\/\/doi.org\/10.1002\/adtp.201900170.","journal-title":"Adv Ther"},{"key":"2501_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202309355","volume":"36","author":"AM L\u00f3pez-Est\u00e9vez","year":"2024","unstructured":"L\u00f3pez-Est\u00e9vez AM, Lapuhs P, Pineiro\u2010Alonso L, Alonso MJ. Personalized cancer nanomedicine: overcoming biological barriers for intracellular delivery of biopharmaceuticals. Adv Mater. 2024;36:2309355. https:\/\/doi.org\/10.1002\/adma.202309355.","journal-title":"Adv Mater"},{"issue":"10","key":"2501_CR46","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1002\/pol.20230916","volume":"62","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Sun H, Giannino J, Wu Y, Cheng C. Biodegradable zwitterionic polymers as PEG alternatives for drug delivery. J Polym Sci. 2024;62(10):2231\u201350. https:\/\/doi.org\/10.1002\/pol.20230916.","journal-title":"J Polym Sci"},{"key":"2501_CR47","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","volume":"3","author":"SS Nogueira","year":"2020","unstructured":"Nogueira SS, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer MA, et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl Nano Mater. 2020;3:10634\u201345. https:\/\/doi.org\/10.1021\/acsanm.0c01834.","journal-title":"ACS Appl Nano Mater"},{"key":"2501_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33889-3","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Pan D, Chen S, Martikainen M-V, K\u00e5rlund A, Ke J, et al. Systematic design of cell membrane coating to improve tumor targeting of nanoparticles. Nat Commun. 2022;13:6181. https:\/\/doi.org\/10.1038\/s41467-022-33889-3.","journal-title":"Nat Commun"},{"key":"2501_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20240043","volume":"5","author":"A Mac\u00e1rio-Soares","year":"2024","unstructured":"Mac\u00e1rio-Soares A, Sousa\u2010Oliveira I, Correia M, Pires PC, Sharma A, Kumar Jha N, et al. Cell membrane and extracellular vesicle membrane\u2010coated nanoparticles: an envisaged approach for the management of skin conditions. View. 2024;5:20240043. https:\/\/doi.org\/10.1002\/VIW.20240043.","journal-title":"View"},{"key":"2501_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113138","volume":"42","author":"F Xu","year":"2023","unstructured":"Xu F, Jiang D, Xu J, Dai H, Fan Q, Fei Z, et al. Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy. Cell Rep. 2023;42:113138. https:\/\/doi.org\/10.1016\/j.celrep.2023.113138.","journal-title":"Cell Rep"},{"key":"2501_CR51","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.2967\/jnumed.120.260687","volume":"62","author":"VIJ Jallinoja","year":"2021","unstructured":"Jallinoja VIJ, Houghton JL. Current landscape in clinical pretargeted radioimmunoimaging and therapy. J Nucl Med. 2021;62:1200\u20136. https:\/\/doi.org\/10.2967\/jnumed.120.260687.","journal-title":"J Nucl Med"},{"key":"2501_CR52","first-page":"S3897","volume":"9","author":"RM Sharkey","year":"2003","unstructured":"Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res. 2003;9:S3897\u2013913.","journal-title":"Clin Cancer Res"},{"key":"2501_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0034-x","volume":"1","author":"X Han","year":"2017","unstructured":"Han X, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. Npj Precision Onc. 2017;1:31. https:\/\/doi.org\/10.1038\/s41698-017-0034-x.","journal-title":"Npj Precision Onc"},{"key":"2501_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114075","volume":"205","author":"A G\u00e9raud","year":"2024","unstructured":"G\u00e9raud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, et al. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer. 2024;205:114075. https:\/\/doi.org\/10.1016\/j.ejca.2024.114075.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2501_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavar\u00e9 R, et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep. 2021;11(1):14397. https:\/\/doi.org\/10.1038\/s41598-021-93842-0.","journal-title":"Sci Rep"},{"key":"2501_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002488","volume":"9","author":"K Dang","year":"2021","unstructured":"Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, et al. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J Immunother Cancer. 2021;9:e002488. https:\/\/doi.org\/10.1136\/jitc-2021-002488.","journal-title":"J Immunother Cancer"},{"key":"2501_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020287","volume":"13","author":"J Middelburg","year":"2021","unstructured":"Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers (Basel). 2021;13:287. https:\/\/doi.org\/10.3390\/cancers13020287.","journal-title":"Cancers (Basel)"},{"key":"2501_CR58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"L Wu","year":"2020","unstructured":"Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer. 2020;1:86\u201398. https:\/\/doi.org\/10.1038\/s43018-019-0004-z.","journal-title":"Nat Cancer"},{"key":"2501_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1523693","volume":"16","author":"Z Ai","year":"2025","unstructured":"Ai Z, Wang B, Song Y, Cheng P, Liu X, Sun P. Prodrug-based bispecific antibodies for cancer therapy: advances and future directions. Front Immunol. 2025;16:1523693. https:\/\/doi.org\/10.3389\/fimmu.2025.1523693.","journal-title":"Front Immunol"},{"key":"2501_CR60","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2373325","volume":"16","author":"AC McCue","year":"2024","unstructured":"McCue AC, Demarest SJ, Froning KJ, Hickey MJ, Antonysamy S, Kuhlman B. Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy. MAbs. 2024;16:2373325. https:\/\/doi.org\/10.1080\/19420862.2024.2373325.","journal-title":"MAbs"},{"key":"2501_CR61","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","volume":"82","author":"LM Boustany","year":"2022","unstructured":"Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, et al. A probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity. Cancer Res. 2022;82:4288\u201398. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2483.","journal-title":"Cancer Res"},{"key":"2501_CR62","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41551-023-01147-6","volume":"8","author":"N Gong","year":"2024","unstructured":"Gong N, Han X, Xue L, Billingsley MM, Huang X, El-Mayta R, et al. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager. Nat Biomed Eng. 2024;8:513\u201328. https:\/\/doi.org\/10.1038\/s41551-023-01147-6.","journal-title":"Nat Biomed Eng"},{"key":"2501_CR63","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"M Zhu","year":"2016","unstructured":"Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, et al. Blinatumomab, a bispecific t-cell engager (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet. 2016;55:1271\u201388. https:\/\/doi.org\/10.1007\/s40262-016-0405-4.","journal-title":"Clin Pharmacokinet"},{"key":"2501_CR64","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1039\/c9md00018f","volume":"10","author":"A Zorzi","year":"2019","unstructured":"Zorzi A, Linciano S, Angelini A. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Medchemcomm. 2019;10:1068\u201381. https:\/\/doi.org\/10.1039\/c9md00018f.","journal-title":"Medchemcomm"},{"key":"2501_CR65","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1021\/acs.biochem.2c00718","volume":"62","author":"Q Cheng","year":"2023","unstructured":"Cheng Q, Zhang X-N, Li J, Chen J, Wang Y, Zhang Y. Synthesis of bispecific antibody conjugates using functionalized poly-ADP-ribose polymers. Biochemistry. 2023;62:1138\u201344. https:\/\/doi.org\/10.1021\/acs.biochem.2c00718.","journal-title":"Biochemistry"},{"key":"2501_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202977","volume":"12","author":"W Zhang","year":"2023","unstructured":"Zhang W, Li D, Xu X, Chen Y, Shi X, Pan Y, et al. A bispecific peptide-polymer conjugate bridging target-effector cells to enhance immunotherapy. Adv Healthc Mater. 2023;12:e2202977. https:\/\/doi.org\/10.1002\/adhm.202202977.","journal-title":"Adv Healthc Mater"},{"key":"2501_CR67","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1158\/1535-7163.MCT-17-1138","volume":"17","author":"W Leconet","year":"2018","unstructured":"Leconet W, Liu H, Guo M, Le Lamer-D\u00e9champs S, Molinier C, Kim S, et al. Anti-PSMA\/CD3 bispecific antibody delivery and antitumor activity using a polymeric depot formulation. Mol Cancer Ther. 2018;17:1927\u201340. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1138.","journal-title":"Mol Cancer Ther"},{"key":"2501_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121166","volume":"278","author":"P-S Wei","year":"2021","unstructured":"Wei P-S, Chen Y-J, Lin S-Y, Chuang K-H, Sheu M-T, Ho H-O. In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 ScFv T-cell\/anti-EGFR fab engager (BiTEE). Biomaterials. 2021;278:121166. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121166.","journal-title":"Biomaterials"},{"key":"2501_CR69","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41375-021-01127-2","volume":"35","author":"K Alhallak","year":"2021","unstructured":"Alhallak K, Sun J, Wasden K, Guenthner N, O\u2019Neal J, Muz B, et al. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia. 2021;35:2346\u201357. https:\/\/doi.org\/10.1038\/s41375-021-01127-2.","journal-title":"Leukemia"},{"key":"2501_CR70","doi-asserted-by":"publisher","first-page":"9661","DOI":"10.1039\/C9NR01904A","volume":"11","author":"M Xu","year":"2019","unstructured":"Xu M, Wen Y, Liu Y, Tan X, Chen X, Zhu X, et al. Hollow mesoporous ruthenium nanoparticles conjugated bispecific antibody for targeted anti-colorectal cancer response of combination therapy. Nanoscale. 2019;11:9661\u201378. https:\/\/doi.org\/10.1039\/C9NR01904A.","journal-title":"Nanoscale"},{"key":"2501_CR71","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jconrel.2022.03.015","volume":"344","author":"W-J Cheng","year":"2022","unstructured":"Cheng W-J, Chuang K-H, Lo Y-J, Chen M, Chen Y-J, Roffler SR, et al. Bispecific T-cell engagers non-covalently decorated drug-loaded pegylated nanocarriers for cancer immunochemotherapy. J Control Release. 2022;344:235\u201348. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.015.","journal-title":"J Control Release"},{"key":"2501_CR72","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","volume":"22","author":"SW Linderman","year":"2025","unstructured":"Linderman SW, DeRidder L, Sanjurjo L, Foote MB, Alonso MJ, Kirtane AR, et al. Enhancing immunotherapy with tumour-responsive nanomaterials. Nat Rev Clin Oncol. 2025;22:262\u201382. https:\/\/doi.org\/10.1038\/s41571-025-01000-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"2501_CR73","doi-asserted-by":"publisher","first-page":"9126","DOI":"10.1021\/acsnano.2c12217","volume":"17","author":"R Fan","year":"2023","unstructured":"Fan R, Chen C, Mu M, Chuan D, Liu H, Hou H, et al. Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for ferroptosis-enhanced glioblastoma immunotherapy. ACS Nano. 2023;17:9126\u201339. https:\/\/doi.org\/10.1021\/acsnano.2c12217.","journal-title":"ACS Nano"},{"key":"2501_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33837","volume":"10","author":"R Li","year":"2024","unstructured":"Li R, Shi X, Zhang J, Liu B, Shen J, Liu H, et al. CaCO3-encapsulated polydopamine with an adsorbed TLR7 agonist for improved tumor photothermal immunotherapy. Heliyon. 2024;10:e33837. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33837.","journal-title":"Heliyon"},{"key":"2501_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215699","volume":"538","author":"G Xu","year":"2022","unstructured":"Xu G, Luo Y, Wang H, Wang Y, Liu B, Wei J. Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Lett. 2022;538:215699. https:\/\/doi.org\/10.1016\/j.canlet.2022.215699.","journal-title":"Cancer Lett"},{"key":"2501_CR76","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, et al. Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26:5869\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1247.","journal-title":"Clin Cancer Res"},{"key":"2501_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1126\/sciimmunol.abd5515","volume":"6","author":"J Douglass","year":"2021","unstructured":"Douglass J, Hsiue EH-C, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, et al. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021;6:57. https:\/\/doi.org\/10.1126\/sciimmunol.abd5515.","journal-title":"Sci Immunol"},{"key":"2501_CR78","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00109-025-02585-2","volume":"103","author":"S Ebrahimi","year":"2025","unstructured":"Ebrahimi S, Lohnes BJ, Khan SA, Peipp M, Bockamp E, Klein C, et al. Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager. J Mol Med. 2025;103:1231\u201347. https:\/\/doi.org\/10.1007\/s00109-025-02585-2.","journal-title":"J Mol Med"},{"key":"2501_CR79","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jconrel.2024.07.032","volume":"373","author":"AM L\u00f3pez-Est\u00e9vez","year":"2024","unstructured":"L\u00f3pez-Est\u00e9vez AM, Sanjurjo L, Turrero \u00c1, Arriaga I, Abrescia NGA, Poveda A, et al. Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors. J Control Release. 2024;373:277\u201392. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.032.","journal-title":"J Control Release"},{"key":"2501_CR80","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910874","volume":"11","author":"HR Salih","year":"2019","unstructured":"Salih HR, Jung G. The challenges of translation. EMBO Mol Med. 2019;11:e10874. https:\/\/doi.org\/10.15252\/emmm.201910874.","journal-title":"EMBO Mol Med"},{"key":"2501_CR81","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.omto.2022.07.003","volume":"26","author":"PS Bhojnagarwala","year":"2022","unstructured":"Bhojnagarwala PS, O\u2019Connell RP, Park D, Liaw K, Ali AR, Bordoloi D, et al. In vivo DNA-launched bispecific T cell engager targeting IL-13R\u03b12 controls tumor growth in an animal model of glioblastoma multiforme. Mol Ther. 2022;26:289\u2013301. https:\/\/doi.org\/10.1016\/j.omto.2022.07.003.","journal-title":"Mol Ther"},{"key":"2501_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0505-4","volume":"7","author":"J De Sostoa","year":"2019","unstructured":"De Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer. 2019;7:1\u201315. https:\/\/doi.org\/10.1186\/s40425-019-0505-4.","journal-title":"J Immunother Cancer"},{"key":"2501_CR83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.omto.2022.12.007","volume":"28","author":"S Basnet","year":"2023","unstructured":"Basnet S, Santos JM, Quixabeira DCA, Clubb JHA, Gr\u00f6nberg-V\u00e4h\u00e4-Koskela SAM, Arias V, et al. Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors. Mol Ther Oncolytics. 2023;28:59\u201373. https:\/\/doi.org\/10.1016\/j.omto.2022.12.007.","journal-title":"Mol Ther Oncolytics"},{"key":"2501_CR84","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nm.4356","volume":"23","author":"CR Stadler","year":"2017","unstructured":"Stadler CR, B\u00e4hr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017;23:815\u20137. https:\/\/doi.org\/10.1038\/nm.4356.","journal-title":"Nat Med"},{"key":"2501_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.adl2720","volume":"16","author":"CR Stadler","year":"2024","unstructured":"Stadler CR, Ellinghaus U, Fischer L, B\u00e4hr-Mahmud H, Rao M, Lindemann C, et al. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human Claudin 6. Sci Transl Med. 2024;16:1\u201313. https:\/\/doi.org\/10.1126\/scitranslmed.adl2720.","journal-title":"Sci Transl Med"},{"key":"2501_CR86","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jconrel.2021.12.029","volume":"342","author":"S Hao","year":"2022","unstructured":"Hao S, Inamdar VV, Sigmund EC, Zhang F, Stephan SB, Watson C, et al. BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology. J Control Release. 2022;342:14\u201325. https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.029.","journal-title":"J Control Release"},{"key":"2501_CR87","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-\u03b3 production. Nat Immunol. 2001;2:269\u201374. https:\/\/doi.org\/10.1038\/85339.","journal-title":"Nat Immunol"},{"key":"2501_CR88","doi-asserted-by":"publisher","unstructured":"Kai X, Zhang Y, Wei B, Tatang D, Angus S, Jin C et al. Tissue-targeted lipid nanoparticle delivery for mRNA encoding bispecific T-cell engager demonstrated potent antitumor effects on both hematological malignancies and solid tumors. J Immunother Cancer. 202;11:A1512\u20133. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.1358. Meeting Abstract: SITC 38th Annual Meeting .","DOI":"10.1136\/jitc-2023-SITC2023"},{"key":"2501_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102860","volume":"15","author":"V Golubovskaya","year":"2023","unstructured":"Golubovskaya V, Sienkiewicz J, Sun J, Huang Y, Hu L, Zhou H, et al. mRNA-lipid nanoparticle (LNP) delivery of humanized EpCAM-CD3 bispecific antibody significantly blocks colorectal cancer tumor growth. Cancers. 2023;15:2860. https:\/\/doi.org\/10.3390\/cancers15102860.","journal-title":"Cancers"},{"key":"2501_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12070808","volume":"12","author":"L Hu","year":"2024","unstructured":"Hu L, Zhang S, Sienkiewicz J, Zhou H, Berahovich R, Sun J, et al. HER2-CD3-Fc bispecific antibody-encoding mRNA delivered by lipid nanoparticles suppresses HER2-positive tumor growth. Vaccines. 2024;12:808. https:\/\/doi.org\/10.3390\/vaccines12070808.","journal-title":"Vaccines"},{"key":"2501_CR91","doi-asserted-by":"publisher","first-page":"12383","DOI":"10.1080\/21655979.2021.2003666","volume":"12","author":"L Wu","year":"2021","unstructured":"Wu L, Wang W, Tian J, Qi C, Cai Z, Yan W, et al. Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery. Bioengineered. 2021;12:12383\u201393. https:\/\/doi.org\/10.1080\/21655979.2021.2003666.","journal-title":"Bioengineered"},{"key":"2501_CR92","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/s41388-024-03066-5","volume":"43","author":"J Zeng","year":"2024","unstructured":"Zeng J, Fang Y, Zhang Z, Lv Z, Wang X, Huang Q, et al. Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4. Oncogene. 2024;43:2244\u201352. https:\/\/doi.org\/10.1038\/s41388-024-03066-5.","journal-title":"Oncogene"},{"key":"2501_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adma.202007603","volume":"33","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, et al. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies. Adv Mater. 2021;33:1\u201311. https:\/\/doi.org\/10.1002\/adma.202007603.","journal-title":"Adv Mater"},{"key":"2501_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1494206","volume":"15","author":"O Hangiu","year":"2025","unstructured":"Hangiu O, Navarro R, Frago S, Rubio-P\u00e9rez L, Tapia-Galisteo A, D\u00edez-Alonso L, et al. Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation. Front Immunol. 2025;15:1494206. https:\/\/doi.org\/10.3389\/fimmu.2024.1494206.","journal-title":"Front Immunol"},{"key":"2501_CR95","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"key":"2501_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202205532","volume":"10","author":"C Huang","year":"2023","unstructured":"Huang C, Duan X, Wang J, Tian Q, Ren Y, Chen K, et al. Lipid nanoparticle delivery system for Mrna encoding B7H3-redirected bispecific antibody displays potent antitumor effects on malignant tumors. Adv Sci. 2023;10:1\u201316. https:\/\/doi.org\/10.1002\/advs.202205532.","journal-title":"Adv Sci"},{"key":"2501_CR97","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345\u201351. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.007.","journal-title":"J Control Release"},{"key":"2501_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9:2629. https:\/\/doi.org\/10.1038\/s41467-018-05096-6.","journal-title":"Nat Commun"},{"key":"2501_CR99","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat Nanotechnol. 2020;15:313\u201320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6.","journal-title":"Nat Nanotechnol"},{"key":"2501_CR100","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41563-023-01472-w","volume":"22","author":"R Zhong","year":"2023","unstructured":"Zhong R, Talebian S, Mendes BB, Wallace G, Langer R, Conde J, et al. Hydrogels for RNA delivery. Nat Mater. 2023;22:818\u201331. https:\/\/doi.org\/10.1038\/s41563-023-01472-w.","journal-title":"Nat Mater"},{"key":"2501_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.142242","volume":"462","author":"J Cai","year":"2023","unstructured":"Cai J, Jiang S, Liao J, Fan H, Peng C, Shi S, et al. Manganese-doped biostimulatory nanoneedle for MRI-visual bispecific antibody gene delivery and immunosuppression reversal as a cancer immunotherapy strategy. Chem Eng J. 2023;462:142242. https:\/\/doi.org\/10.1016\/j.cej.2023.142242.","journal-title":"Chem Eng J"},{"key":"2501_CR102","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903. https:\/\/doi.org\/10.1084\/jem.20230903.","journal-title":"J Exp Med"},{"key":"2501_CR103","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","volume":"40","author":"B Blanco","year":"2019","unstructured":"Blanco B, Compte M, Lykkemark S, Sanz L, Alvarez-Vallina L. T cell-redirecting strategies to stab tumors: beyond cars and bispecific antibodies. Trends Immunol. 2019;40:243\u201357. https:\/\/doi.org\/10.1016\/j.it.2019.01.008.","journal-title":"Trends Immunol"},{"key":"2501_CR104","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.4049\/jimmunol.171.2.1070","volume":"171","author":"B Blanco","year":"2003","unstructured":"Blanco B, Holliger P, Vile RG, Alvarez-Vallina L. Induction of human T lymphocyte cytotoxicity and Inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol. 2003;171:1070\u20137. https:\/\/doi.org\/10.4049\/jimmunol.171.2.1070.","journal-title":"J Immunol"},{"key":"2501_CR105","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-21-0853","volume":"10","author":"B Blanco","year":"2022","unstructured":"Blanco B, Ram\u00edrez-Fern\u00e1ndez \u00c1, Bueno C, Argem\u00ed-Muntadas L, Fuentes P, Aguilar-Sope\u00f1a \u00d3, et al. Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers. Cancer Immunol Res. 2022;10:498\u2013511. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0853.","journal-title":"Cancer Immunol Res"},{"key":"2501_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.38","volume":"6","author":"X Liu","year":"2016","unstructured":"Liu X, Barrett DM, Jiang S, Fang C, Kalos M, Grupp SA, et al. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J. 2016;6:e430. https:\/\/doi.org\/10.1038\/bcj.2016.38.","journal-title":"Blood Cancer J"},{"key":"2501_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/srep27130","volume":"6","author":"MP Velasquez","year":"2016","unstructured":"Velasquez MP, Torres D, Iwahori K, Kakarla S, Arber C, Rodriguez-Cruz T, et al. T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive malignancies. Sci Rep. 2016;6:27130. https:\/\/doi.org\/10.1038\/srep27130.","journal-title":"Sci Rep"},{"key":"2501_CR108","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1126\/scitranslmed.adg7962","volume":"16","author":"L D\u00edez-Alonso","year":"2024","unstructured":"D\u00edez-Alonso L, Falgas A, Arroyo-R\u00f3denas J, Romenc\u00edn PA, Mart\u00ednez A, G\u00f3mez-Rosel M, et al. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo. Sci Transl Med. 2024;16:734. https:\/\/doi.org\/10.1126\/scitranslmed.adg7962.","journal-title":"Sci Transl Med"},{"key":"2501_CR109","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/mt.2016.116","volume":"24","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, et al. CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia. Mol Ther. 2016;24:1615\u201326. https:\/\/doi.org\/10.1038\/mt.2016.116.","journal-title":"Mol Ther"},{"key":"2501_CR110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005333","volume":"10","author":"A Jim\u00e9nez-Reinoso","year":"2022","unstructured":"Jim\u00e9nez-Reinoso A, Tirado N, Martinez-Moreno A, D\u00edaz VM, Garc\u00eda-Peydr\u00f3 M, Hangiu O, et al. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers. J Immunother Cancer. 2022;10:e005333. https:\/\/doi.org\/10.1136\/jitc-2022-005333.","journal-title":"J Immunother Cancer"},{"key":"2501_CR111","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/sj.cgt.7701021","volume":"14","author":"M Compte","year":"2007","unstructured":"Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A, et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther. 2007;14:380\u20138. https:\/\/doi.org\/10.1038\/sj.cgt.7701021.","journal-title":"Cancer Gene Ther"},{"key":"2501_CR112","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1634\/stemcells.2008-0831","volume":"27","author":"M Compte","year":"2009","unstructured":"Compte M, Cuesta AM, S\u00e1nchez-Mart\u00edn D, Alonso-Camino V, Vicario JL, Sanz L, et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells. 2009;27:753\u201360. https:\/\/doi.org\/10.1634\/stemcells.2008-0831.","journal-title":"Stem Cells"},{"key":"2501_CR113","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1182\/blood-2003-04-1193","volume":"102","author":"F Djouad","year":"2003","unstructured":"Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102:3837\u201344. https:\/\/doi.org\/10.1182\/blood-2003-04-1193.","journal-title":"Blood"},{"key":"2501_CR114","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.24.554523","author":"TF Hill","year":"2023","unstructured":"Hill TF, Narvekar P, Asher G, Camp N, Thomas KR, Tasian SK, et al. Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing. Preprint [bioRxiv]. 2023. https:\/\/doi.org\/10.1101\/2023.08.24.554523.","journal-title":"Preprint [bioRxiv]"},{"key":"2501_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207276","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lam K-P, Xu S. Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy. Front Immunol. 2023;14:1207276. https:\/\/doi.org\/10.3389\/fimmu.2023.1207276.","journal-title":"Front Immunol"},{"key":"2501_CR116","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001202","volume":"8","author":"JL Gardell","year":"2020","unstructured":"Gardell JL, Matsumoto LR, Chinn H, DeGolier KR, Kreuser SA, Prieskorn B, et al. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma. J Immunother Cancer. 2020;8:e001202. https:\/\/doi.org\/10.1136\/jitc-2020-001202.","journal-title":"J Immunother Cancer"},{"key":"2501_CR117","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3343\/alm.2023.0382","volume":"44","author":"NK Lee","year":"2024","unstructured":"Lee NK, Chang JW. Manufacturing cell and gene therapies: challenges in clinical translation. Ann Lab Med. 2024;44:314\u201323. https:\/\/doi.org\/10.3343\/alm.2023.0382.","journal-title":"Ann Lab Med"},{"key":"2501_CR118","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4614-9632-8_1","volume":"1121","author":"LM Mir","year":"2014","unstructured":"Mir LM. Electroporation-based gene therapy: recent evolution in the mechanism description and technology developments. Methods Mol Biol. 2014;1121:3\u201323. https:\/\/doi.org\/10.1007\/978-1-4614-9632-8_1.","journal-title":"Methods Mol Biol"},{"key":"2501_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00150-z","author":"A Mullard","year":"2024","unstructured":"Mullard A. In vivo CAR T cells move into clinical trials. Nat Rev Drug Discov. 2024. https:\/\/doi.org\/10.1038\/d41573-024-00150-z.","journal-title":"Nat Rev Drug Discov"},{"key":"2501_CR120","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"key":"2501_CR121","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388:1311\u20137. https:\/\/doi.org\/10.1126\/science.ads8473.","journal-title":"Science"},{"issue":"16suppl","key":"2501_CR122","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/JCO.2025.43.16_suppl.2501","volume":"43","author":"TA Yap","year":"2025","unstructured":"Yap TA, Hernando-Calvo AH, Calvo E, Moreno V, Marquez R, Papadopoulos P KP, et al. First-in-human phase I\/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors. J Clin Oncol. 2025;43(16suppl):2501\u20132501. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2501. Meeting Abstract: 2025 ASCO Annual Meeting I.","journal-title":"J Clin Oncol"},{"key":"2501_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s40643-024-00796-y","volume":"11","author":"N Ingavat","year":"2024","unstructured":"Ingavat N, Dzulkiflie N, Liew JM, Wang X, Leong E, Loh HP, et al. Investigation on environmental factors contributing to bispecific antibody stability and the reversal of self-associated aggregates. Bioresour Bioprocess. 2024;11:82. https:\/\/doi.org\/10.1186\/s40643-024-00796-y.","journal-title":"Bioresour Bioprocess"},{"key":"2501_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02002-z","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi Y, Shi M, Wang Y, You J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Sig Transduct Target Ther. 2024;9:322. https:\/\/doi.org\/10.1038\/s41392-024-02002-z.","journal-title":"Sig Transduct Target Ther"},{"key":"2501_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s44301-025-00008-2","volume":"1","author":"A Fortune","year":"2025","unstructured":"Fortune A, Aime A, Raymond D, Kumar S. Nanotechnology in medicine: a double-edged sword for health outcomes. Health Nanotechnol. 2025;1:9. https:\/\/doi.org\/10.1186\/s44301-025-00008-2.","journal-title":"Health Nanotechnol"},{"key":"2501_CR126","doi-asserted-by":"publisher","DOI":"10.1039\/d5na00323g","author":"NW Nabih","year":"2025","unstructured":"Nabih NW, Hassan HAFM, Preis E, Schaefer J, Babker A, Abbas AM, et al. Antibody-functionalized lipid nanocarriers for RNA-based cancer gene therapy: advances and challenges in targeted delivery. Nanoscale Adv. 2025. https:\/\/doi.org\/10.1039\/d5na00323g.","journal-title":"Nanoscale Adv"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02501-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02501-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02501-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:40:22Z","timestamp":1763448022000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02501-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2501"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02501-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"MJA has financial interest in Libera Bio, Inc, a company related to immunotherapy. LAV has financial interests in Leadartis, Inc, and STAb Therapeutics, Inc companies related to immunotherapy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}